vs

Side-by-side financial comparison of Labcorp (LH) and EchoStar CORP (SATS). Click either name above to swap in a different company.

EchoStar CORP is the larger business by last-quarter revenue ($3.8B vs $3.5B, roughly 1.1× Labcorp). Labcorp runs the higher net margin — 4.7% vs -31.8%, a 36.5% gap on every dollar of revenue. On growth, Labcorp posted the faster year-over-year revenue change (5.6% vs -4.3%). Labcorp produced more free cash flow last quarter ($490.3M vs $-583.4M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs -2.8%).

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

TiVo Inc. v. EchoStar Corp. is a case stretching from 2004 to 2011, which took place in the United States District Court for the Eastern District of Texas and the United States Court of Appeals for the Federal Circuit. TiVo Inc. sued EchoStar Corp. claiming patent infringement of a DVR technology. The issues addressed during litigation included patent infringement, wording of injunctions, infringing product redesign, contempt of court orders, and contempt sanctions. Ultimately, the court held...

LH vs SATS — Head-to-Head

Bigger by revenue
SATS
SATS
1.1× larger
SATS
$3.8B
$3.5B
LH
Growing faster (revenue YoY)
LH
LH
+9.9% gap
LH
5.6%
-4.3%
SATS
Higher net margin
LH
LH
36.5% more per $
LH
4.7%
-31.8%
SATS
More free cash flow
LH
LH
$1.1B more FCF
LH
$490.3M
$-583.4M
SATS
Faster 2-yr revenue CAGR
LH
LH
Annualised
LH
5.2%
-2.8%
SATS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LH
LH
SATS
SATS
Revenue
$3.5B
$3.8B
Net Profit
$164.7M
$-1.2B
Gross Margin
28.2%
Operating Margin
7.6%
-20.5%
Net Margin
4.7%
-31.8%
Revenue YoY
5.6%
-4.3%
Net Profit YoY
14.9%
-460.1%
EPS (diluted)
$1.98
$-4.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LH
LH
SATS
SATS
Q4 25
$3.5B
$3.8B
Q3 25
$3.6B
$3.6B
Q2 25
$3.5B
$3.7B
Q1 25
$3.3B
$3.9B
Q4 24
$3.3B
$4.0B
Q3 24
$3.3B
$3.9B
Q2 24
$3.2B
$4.0B
Q1 24
$3.2B
$4.0B
Net Profit
LH
LH
SATS
SATS
Q4 25
$164.7M
$-1.2B
Q3 25
$261.1M
$-12.8B
Q2 25
$237.9M
$-306.1M
Q1 25
$212.8M
$-202.7M
Q4 24
$143.4M
$335.2M
Q3 24
$169.3M
$-141.8M
Q2 24
$205.3M
$-205.6M
Q1 24
$228.0M
$-107.4M
Gross Margin
LH
LH
SATS
SATS
Q4 25
28.2%
Q3 25
28.8%
Q2 25
29.7%
Q1 25
28.3%
Q4 24
26.9%
Q3 24
27.6%
Q2 24
28.8%
Q1 24
28.2%
Operating Margin
LH
LH
SATS
SATS
Q4 25
7.6%
-20.5%
Q3 25
11.1%
-460.5%
Q2 25
11.2%
-5.7%
Q1 25
9.7%
-2.3%
Q4 24
6.5%
-1.6%
Q3 24
7.7%
-4.1%
Q2 24
9.2%
-1.7%
Q1 24
10.1%
-0.4%
Net Margin
LH
LH
SATS
SATS
Q4 25
4.7%
-31.8%
Q3 25
7.3%
-353.6%
Q2 25
6.7%
-8.2%
Q1 25
6.4%
-5.2%
Q4 24
4.3%
8.5%
Q3 24
5.2%
-3.6%
Q2 24
6.4%
-5.2%
Q1 24
7.2%
-2.7%
EPS (diluted)
LH
LH
SATS
SATS
Q4 25
$1.98
$-4.27
Q3 25
$3.12
$-44.37
Q2 25
$2.84
$-1.06
Q1 25
$2.52
$-0.71
Q4 24
$1.72
$1.24
Q3 24
$2.00
$-0.52
Q2 24
$2.43
$-0.76
Q1 24
$2.69
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LH
LH
SATS
SATS
Cash + ST InvestmentsLiquidity on hand
$532.3M
$3.0B
Total DebtLower is stronger
$18.7B
Stockholders' EquityBook value
$8.6B
$5.8B
Total Assets
$18.4B
$43.0B
Debt / EquityLower = less leverage
3.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LH
LH
SATS
SATS
Q4 25
$532.3M
$3.0B
Q3 25
$598.1M
$3.9B
Q2 25
$647.3M
$4.3B
Q1 25
$369.4M
$5.1B
Q4 24
$1.5B
$5.5B
Q3 24
$1.5B
$674.4M
Q2 24
$265.1M
$520.6M
Q1 24
$99.3M
$766.4M
Total Debt
LH
LH
SATS
SATS
Q4 25
$18.7B
Q3 25
$21.8B
Q2 25
$25.4B
Q1 25
$25.3B
Q4 24
$25.7B
Q3 24
Q2 24
Q1 24
$951.0M
Stockholders' Equity
LH
LH
SATS
SATS
Q4 25
$8.6B
$5.8B
Q3 25
$8.7B
$7.0B
Q2 25
$8.5B
$19.7B
Q1 25
$8.3B
$20.0B
Q4 24
$8.1B
$20.2B
Q3 24
$8.2B
$19.4B
Q2 24
$8.0B
$19.6B
Q1 24
$8.0B
$19.8B
Total Assets
LH
LH
SATS
SATS
Q4 25
$18.4B
$43.0B
Q3 25
$18.3B
$45.3B
Q2 25
$18.1B
$59.9B
Q1 25
$17.6B
$60.6B
Q4 24
$18.4B
$60.9B
Q3 24
$18.6B
$57.5B
Q2 24
$16.7B
$55.3B
Q1 24
$16.5B
$55.6B
Debt / Equity
LH
LH
SATS
SATS
Q4 25
3.24×
Q3 25
3.13×
Q2 25
1.29×
Q1 25
1.27×
Q4 24
1.27×
Q3 24
Q2 24
Q1 24
0.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LH
LH
SATS
SATS
Operating Cash FlowLast quarter
$614.2M
$-425.3M
Free Cash FlowOCF − Capex
$490.3M
$-583.4M
FCF MarginFCF / Revenue
13.9%
-15.4%
Capex IntensityCapex / Revenue
3.5%
4.2%
Cash ConversionOCF / Net Profit
3.73×
TTM Free Cash FlowTrailing 4 quarters
$1.2B
$-1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LH
LH
SATS
SATS
Q4 25
$614.2M
$-425.3M
Q3 25
$387.2M
$111.7M
Q2 25
$620.6M
$7.5M
Q1 25
$18.5M
$206.8M
Q4 24
$777.2M
$45.6M
Q3 24
$277.3M
$276.2M
Q2 24
$561.1M
$479.7M
Q1 24
$-29.8M
$451.3M
Free Cash Flow
LH
LH
SATS
SATS
Q4 25
$490.3M
$-583.4M
Q3 25
$280.5M
$-144.4M
Q2 25
$542.7M
$-285.7M
Q1 25
$-107.5M
$-51.7M
Q4 24
$665.1M
$-298.7M
Q3 24
$161.5M
$-57.5M
Q2 24
$432.9M
$132.4M
Q1 24
$-163.6M
$-68.4M
FCF Margin
LH
LH
SATS
SATS
Q4 25
13.9%
-15.4%
Q3 25
7.9%
-4.0%
Q2 25
15.4%
-7.7%
Q1 25
-3.2%
-1.3%
Q4 24
20.0%
-7.5%
Q3 24
4.9%
-1.5%
Q2 24
13.4%
3.3%
Q1 24
-5.2%
-1.7%
Capex Intensity
LH
LH
SATS
SATS
Q4 25
3.5%
4.2%
Q3 25
3.0%
7.1%
Q2 25
2.2%
7.9%
Q1 25
3.8%
6.7%
Q4 24
3.4%
8.7%
Q3 24
3.5%
8.6%
Q2 24
4.0%
8.8%
Q1 24
4.2%
12.9%
Cash Conversion
LH
LH
SATS
SATS
Q4 25
3.73×
Q3 25
1.48×
Q2 25
2.61×
Q1 25
0.09×
Q4 24
5.42×
0.14×
Q3 24
1.64×
Q2 24
2.73×
Q1 24
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LH
LH

Diagnostics$2.7B78%
Biopharma Laboratory Services$793.0M23%

SATS
SATS

Pay Tv$2.4B62%
Wireless Services And Related Revenue$846.5M22%
Equipment Sales And Other Revenue$346.5M9%
Broadband And Satellite Services And Other Revenue$264.1M7%

Related Comparisons